# Simvastatin Plus Rifaximin in Decompensated Cirrhosis

> **NCT03150459** · PHASE2 · COMPLETED · sponsor: **Judit Pich** · enrollment: 44 (actual)

## Conditions studied

- Cirrhoses, Liver

## Interventions

- **DRUG:** Simvastatin 20 mg
- **DRUG:** Simvastatin 40mg
- **DRUG:** Rifaximin 400 mg
- **OTHER:** Placebo of Simvastatin
- **OTHER:** Placebo of Rifaximin

## Key facts

- **NCT ID:** NCT03150459
- **Lead sponsor:** Judit Pich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-26
- **Primary completion:** 2018-03-12
- **Final completion:** 2018-03-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03150459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03150459, "Simvastatin Plus Rifaximin in Decompensated Cirrhosis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03150459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*